Kaitlyn D’Onofrio

DocwireNews

Although methylphenidate, modafinil, and amantadine are often prescribed to treat fatigue in patients with multiple sclerosis (MS), data on their use are unclear. A study compared their efficacy against one another and placebo in patients with MS fatigue.
This was a randomized, placebo-controlled, four-sequence, four-period, crossover, double-blind trial that recruited patients with MS whose Modified Fatigue Impact Scale (MFIS) score was &gt;33. Patients were given oral amantadine (up to 100 mg twice daily), modafinil (up to 100 mg twice daily), methylphenidate (up to 10 mg twice daily), or placebo for up to six weeks. The intention was to give all patients all four study medications in one of four different sequences, using a two-week washout period between each medication. The main outcome measure was MFIS, assessed when the patient was taking the highest-tolerated dose at week five of each medication period.
A total of 141 patients were randomized to one of four medication sequences: amantadine, placebo, modafinil, and methylphenidate (n=35 [25%]); placebo, methylphenidate, amantadine, and modafinil sequence (n=34 [24%]); modafinil, amantadine, methylphenidate, and placebo (n=35 [25%]); and methylphenidate, modafinil, placebo, and amantadine (n=37 [26%]). Of the 141 patients randomized, data were available for 136 for the intention-to-treat analysis of the primary outcome.
The estimated mean MFIS total score at baseline was 51.3 (95% confidence interval [CI], 49-53.6). Estimated mean MFIS values at the maximal tolerated doses were: placebo, 40.6 (95% CI, 38.2-43.1); amantadine, 41.3 (95% CI, 38.8-43.7); modafinil, 39.0 (95% CI, 36.6-41.4); and methylphenidate, 38.6 (95% CI, 36.2-41; P=0.20 for the overall medication effect in the linear mixed-effect regression model). Adverse events (AEs) were more commonly reported among patients taking amantadine (n=49/127 [39%]), modafinil (n=50/125 [40%]), and methylphenidate (n=51/129 [40%]) compared with placebo (n=38/124 [31%]). There were three AEs recorded during the study: pulmonary embolism and myocarditis, both while taking amantadine, and an MS exacerbation that necessitated hospitalization, while taking modafinil.
“Amantadine, modafinil, and methylphenidate were not superior to placebo in improving MS fatigue and caused more frequent AEs. The results of this study do not support an indiscriminate use of amantadine, modafinil, or methylphenidate for the treatment of fatigue in MS,” the study authors concluded.

Katy Marshall

SSTR Antagonist Versus SSTR Agonist in Patients With GEP-NETs

GEP-NETs

Rob Dillard

A Novel Method for Effectively Diagnosing Autism

ADHD

Kaitlyn Kosko

How Timing of Chemotherapy After SCLC Diagnosis Affects Survival

Small Cell Lung Cancer

Latest News

A Comparison of Three Medications for MS Fatigue

Multiple Sclerosis

Although methylphenidate, modafinil, and amantadine are often prescribed to treat fatigue in patients with multiple sclerosis (MS), data on their use are unclear. A study ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Diabetes

Neurology

Rheumatology

Gastroenterology

Pulmonology

Ophthalmology

Infectious Diseases

Health and Wellness

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Fellow on Call

Healthcare Unfiltered

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Career Center

Expert Interviews

Subscribe